Close menu




December 1st, 2020 | 10:23 CET

BP, Triumph Gold, K+S - who offers the best trading opportunities?

  • Investments
Photo credits: pixabay.com

The asset class "commodities" offers investors a broad and exciting investment universe. Especially the high cyclicality of commodity prices provides opportunities. When Gold & Co is in fashion, stocks that operate in this field often develop explosively. But also, commodities that are not among the favorites of investors at times, or are subject to strong fluctuations, such as oil & gas or potash, offer good (countercyclical) investment and trading opportunities.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: CA8968121043 , GB0007980591 , DE000KSAG888

Table of contents:


    BP PLC - 30% price increase in the last weeks, use volatility for trading

    The price of oil has gone off the rails this year. The supply and demand situation is difficult to assess given the fear of recession and the power games of significant players. The volatility was partly absurd.

    It is therefore hardly surprising that large oil companies are among the worst money destroyers in 2020. The share price charts were correspondingly positive. In recent weeks, however, the sentiment of the oil industry has also improved in the course of the generally good stock market phase. The BP share gained 30% last month. The payment of a dividend and even the continued adherence to payouts may seem like a marginal note, but it is not, given the disastrous figures. All because BP is demonstrating financial strength and sending a clear signal that it can successfully adapt structures and costs through a transformation process.

    In the first nine months of the financial year, the industry heavyweight posted a loss of no less than USD 21.7 billion, compared with a profit of USD 4 billion a year earlier. But the worst is probably behind the shareholders because the terrible loss stems mainly from Q2. The third quarter was "only" in the red with USD 450 million. Nevertheless, it may be too early to give the all-clear. For the disagreement within the oil network, Opec+ over an extension of production cuts is causing dark clouds to gather again. No reason for bad mood though - volatile stock market phases are full of trading opportunities.

    TRIUMPH GOLD CORP - bet on the further rise of gold and copper

    Gold is the best-known crisis currency. We have seen this impressively in recent months. Even though the price of the precious metal has recently fallen, experts agree that the price can only rise in the medium term. For a completely different reason, the industrial metal, copper, has developed strongly this year. The forecast demand in the wake of electromobility suggests that the gap between supply and demand will diverge significantly in the future. It is certainly not a bad idea to position oneself in the two raw materials.

    With shares in Triumph Gold, investors can do just that. Triumph Gold Corp is a mineral exploration Company currently focused on its 100% owned Freegold Mountain project in the Yukon. The property is located in the gold-copper belt of the Dawson Range, where the Casino copper deposit, the Coffee gold deposit and the Klaza gold prospect, are also located.

    The Vancouver-based Company currently has a market capitalization of CAD 25 million. The stock has lost approximately 50% over the summer and now offers an attractive level for (post) purchases.

    K+S AG - Commerzbank sees further price potential of 30%

    In recent weeks, the price of the K+S share has experienced a rollercoaster ride. After a long dry spell, the share finally appeared to be heading for liberation in mid-October with the announcement that it intended to sell its salt business in North and South America. However, the share price quickly retreated from the price level of over EUR 7 and corrected to EUR 5.66.

    Today, the share is 2 euros higher again. What are the reasons? Several analysts have now issued price targets of over EUR 7. Commerzbank stood out particularly positively last Friday. The Coba analyst upgraded K+S from "hold" to "buy" and increased the target price from EUR 7 to EUR 10! The expert cited as reasons, the unexpectedly high proceeds expected from the sale of the American salt business, a significant reduction in balance sheet risks after write-downs, and a positive outlook.

    As already mentioned, volatility offers trading opportunities.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read